KalVista Pharmaceuticals: Funding, Investors & Team (Oct 2026)
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
KalVista Pharmaceuticals has raised $397M across 3 funding rounds on record, the most recent an undisclosed round of $179M announced in Nov 2024.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
KalVista Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: Nov 2024.
KalVista Pharmaceuticals Funding Rounds
KalVista Pharmaceuticals raised $58.0M in an undisclosed round announced in Dec 2022.
1.2 years later, an undisclosed round of $160M was announced in Feb 2024.
9 months later, an undisclosed round of $179M was announced in Nov 2024.
KalVista Pharmaceuticals Founders and Leadership Team
No contact details are on record for this team yet.
KalVista Pharmaceuticals Funding Compared to Other Biotechnology Startups
KalVista Pharmaceuticals' latest round of $179M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like KalVista Pharmaceuticals in Biotechnology and Cambridge
Companies Similar to KalVista Pharmaceuticals
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
KalVista Pharmaceuticals Funding FAQs
What does KalVista Pharmaceuticals do?
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema (DME). KalVista is developing novel plasma kallikrein inhibitors, which represents a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries. KalVista has an advanced pre-clinical product pipeline resulting from over 20 years of leading pharmaceutical discovery in the field of serine protease inhibitors and is targeting both intravitreal injection and oral administration. Although VEGF inhibitors clearly can benefit DME, a significant number of patients do not respond fully to these agents and have limited treatment options. Plasma kallikrein inhibitors target a distinct molecular pathway and as such have the potential to offer those patients an effective treatment option.
How much funding has KalVista Pharmaceuticals raised?
KalVista Pharmaceuticals has raised $397M across 3 rounds on record. The most recent is an undisclosed round of $179M announced in Nov 2024.
When did KalVista Pharmaceuticals last raise funding?
KalVista Pharmaceuticals' most recent funding round on record is an undisclosed round of $179M, announced in Nov 2024.
Who founded KalVista Pharmaceuticals?
FundedIQ lists Edward P Feener (Founder), Lloyd P Aiello (Founder) at KalVista Pharmaceuticals.
Where is KalVista Pharmaceuticals headquartered?
KalVista Pharmaceuticals is based in Cambridge, Massachusetts, United States.
How many employees does KalVista Pharmaceuticals have?
KalVista Pharmaceuticals is in the 101-250 employee band.
How does KalVista Pharmaceuticals' funding compare to other Biotechnology startups?
KalVista Pharmaceuticals' latest round of $179M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's KalVista Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for KalVista Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.